Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim

FTC demands Martin Shkreli divest his pharma stocks

The FTC asked a federal court to hold Martin Shkreli in contempt for violating a court order banning him from working in the pharmaceutical industry

FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation

FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation

Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim

Shkreli was banned from the pharmaceutical industry after a trial found that he organized an illegal scheme to perpetuate a monopoly for the drug Daraprim.

FTC Files Contempt Motion Against Martin Shkreli for Alleged Pharmaceutical Industry Involvement

The Federal Trade Commission (FTC) has filed a motion in federal court requesting that Martin Shkreli be held in contempt for allegedly violating a previous court order that prohibits him from participating in the pharmaceutical industry. The agency asserts that Shkreli breached the terms of his 2022 ban by maintaining financial interests and engaging in stock trades related to pharmaceutical companies. The legal filing follows a permanent injun…